Open AccessNeurostimulation‐guided Anal Intrasphincteric Botulinum Toxin Injection in Children With Hirschsprung Disease
Author(s) -
LouisBorrione Claude,
Faure Alice,
Garnier Sarah,
Guys JeanMichel,
Merrot Thierry,
Héry Géraldine,
Dariel Anne
Publication year - 2019
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002204
Subject(s) - medicine , neurostimulation , botulinum toxin , fecal incontinence , cohort , enterocolitis , external anal sphincter , constipation , hirschsprung's disease , internal anal sphincter , gastroenterology , surgery , anesthesia , disease , anal canal , rectum , stimulation
Objectives: In Hirschsprung disease (HD), despite successful surgical treatment, 50% of children experience long‐term functional gastrointestinal problems, particularly chronic functional obstructive symptoms. We report our experience regarding clinical effects of neurostimulation‐guided anal intrasphincteric botulinum toxin (BT) injections on postoperative obstructive symptoms attributed to a nonrelaxing anal sphincter complex in HD patients. Methods: In this monocenter cohort study, 15 HD patients with postoperative functional intestinal obstructive symptoms received neurostimulation‐guided anal intrasphincteric BT injections. Short‐, medium‐, and long‐term effects were evaluated. The Bristol stool form scale was used to assess stool consistency, and the Jorge‐Wexner (JW) score to assess fecal continence. Results: The median age at first injection was 4 years. In the short‐term, a significant improvement in stool consistency was noted in 12 of 14 patients ( P = 0.0001) and JW score decreased for 14 of 15 patients ( P = 0.001). In the medium‐term, JW score significantly decreased for all patients ( P = 0.0001), with an improvement of 50% or more for 10 patients (66.7%). In the long term, 83.3% of patients had normal stool consistency and JW score was <3 for all. Recurrent enterocolitis decreased from 86.7% to 8.3%. A complete resolution of all symptoms without further medication was observed in 66.7% of patients in the long term. Conclusions: Intrasphincteric BT injection was a safe, effective, and durable option for the management of postoperative functional intestinal obstructive symptoms in HD. The use of neurostimulator guidance for specific delivery of BT to muscular fibers of nonrelaxing anal sphincter complex takes into consideration the variability of patient's anatomy secondary to curative surgery.